Prognostic Role of HER-2 according to Lymph Node Involvement in Invasive Ductal Carcinoma of Breast.
- Author:
Seung Sang KO
1
;
Min Hee HUR
;
Hae Kyung LEE
;
Sung Soo KANG
;
Jee Hyun LEE
;
Yi Kyeong CHUN
;
Kyung Mi PARK
;
Yong Koo PARK
Author Information
1. Department of Surgery, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. sungsoo.kang@samsung.com
- Publication Type:Original Article
- Keywords:
HER-2;
Invasive ductal carcinoma;
Prognosis
- MeSH:
Breast Neoplasms;
Breast*;
Carcinoma, Ductal*;
Disease-Free Survival;
Fluorescence;
Humans;
In Situ Hybridization;
Lymph Nodes*;
Multivariate Analysis;
Prognosis
- From:Journal of the Korean Surgical Society
2005;69(2):97-106
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was conducted to investigate the prognostic value of HER2 in breast cancer patients. METHODS: A total of 100 consecutive formalin-fixed, paraffin- embedded sections of invasive ductal carcinomas were evaluated by immunohistochemical staining (IHC) and a fluorescence in situ hybridization (FISH) assay for HER2. The cases of 0/1+ IHC were regarded as negative and 3+ as positive. Among the 100 cases tested by IHC, the 2+ cases were confirmed by FISH. RESULTS: Twenty-seven of 100 cases (27%) were confirmed positive for HER-2, which was significantly correlated with the nuclear grade (NG), ER and PR (P=0.014, P=0.004, and P=0.023, respectively). The mean disease-free survival periods (DFS) and overall survival periods (OS) of the HER-2-positive and -negative patients were 64.6+/-6 months and 82+/-3 months (P=0.0031), and 70+/-6 months and 85+/-2 months, respectively (P=0.0096). Of the 48 axillary lymph node (LN) positive patients, the mean DFS and OS of the HER-2-positive and -negative patients were 46+/-9 months and 80+/-4 months (P=0.0007) and 54+/-9 months and 83+/-4 months, respectively (P= 0.001). In the LN negative patients; however, HER-2 overexpression showed no significant correlation with the prognosis. In a multivariate analysis, DFS was significantly correlated with LN involvement and HER-2 overexpression (P=0.015, and P=0.0396, respectively). However, with regard to the OS. LN involvement and NG were statistically significant (P=0.041, and P=0.0125, respectively). CONCLUSION: This study indicates that HER-2 overexpression may play a useful role as an indicator of poor prognosis in invasive ductal carcinoma of breast, especially in LN positive patients.
